Why the study?
Does aggressive cholesterol lowering and low-dose warfarin improve angiographic changes and clinical events in patients with and without diabetes 1-11 years after CABG?
Population
1,351 patients, including 116 diabetic and 1,235 nondiabetic patients.
Comparison
Aggressive cholesterol-lowering and low-dose… vs Moderate cholesterol-lowering and placebo
Design
RCT, randomized, double-blind
Follow-up
4.3 years
Authors
Loading...
Supports aggressive cholesterol lowering post-CABG in diabetics; confirms comparable angiographic benefits versus nondiabetics despite higher event rates.
Does aggressive cholesterol lowering and low-dose warfarin improve angiographic changes and clinical events in patients with and without diabetes 1-11 years after CABG?
Aggressive cholesterol lowering provides comparable angiographic and clinical benefits in diabetic and nondiabetic patients after CABG, despite diabetic patients having higher baseline risk and event rates.
Hoogwerf et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: